Juan Carlos Fierro-Pineda, Hua-Ling Tsai, Amanda L Blackford, Andrew Cluster, Emi H Caywood, Jignesh Dalal, Jeffrey H Davis, R Maarten Egeler, Jeffrey Huo, Michelle Hudspeth, Amy K Keating, Susan S Kelly, Joerg Krueger, Dean A Lee, Leslie Elaine Lehmann, Lisa Madden, Benjamin R Oshrine, Michael A Pulsipher, Terry J Fry, Heather J Symons
Promising results have been reported for adult patients with high-risk hematologic malignancies undergoing haploidentical bone marrow transplant (haploBMT) with post-transplantation cyclophosphamide (PTCy). We report results from the first multicenter trial for pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndrome (MDS) in the US and Canada in the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC). Nine centers transplanted 32 patients with acute leukemias or MDS with myeloablative conditioning (MAC), haploBMT with PTCy, mycophenolate mofetil, and tacrolimus...
May 31, 2023: Blood Advances